Hawchar Fatime, Rao Cristina, Akil Ali, Mehta Yatin, Rugg Christopher, Scheier Joerg, Adamson Harriet, Deliargyris Efthymios, Molnar Zsolt
Department of Anaesthesiology and Intensive Therapy, University of Szeged, 6 Semmelweis Str., H-6725 Szeged, Hungary.
Cytosorbents Europe GmbH, Müggelseedamm 131, 12587 Berlin, Germany.
Biomedicines. 2021 Jul 1;9(7):768. doi: 10.3390/biomedicines9070768.
Hemodynamic instability due to dysregulated host response is a life-threatening condition requiring vasopressors and vital organ support. Hemoadsorption with Cytosorb has proven to be effective in reducing cytokines and possibly in attenuating the devastating effects of the cytokine storm originating from the immune over-response to the initial insult. We reviewed the PubMed database to assess evidence of the impact of Cytosorb on norepinephrine needs in the critically ill. We further analyzed those studies including data on control cohorts in a comparative pooled analysis, defining a treatment effect as the standardized mean differences in relative reductions in vasopressor dosage at 24 h. The literature search returned 33 eligible studies. We found evidence of a significant reduction in norepinephrine requirement after treatment: median before, 0.55 (IQR: 0.39-0.90); after, 0.09 (0.00-0.25) μg/kg/min, < 0.001. The pooled effect size at 24 h was large, though characterized by high heterogeneity. In light of the importance of a quick resolution of hemodynamic instability in the critically ill, further research is encouraged to enrich knowledge on the potentials of the therapy.
由于宿主反应失调导致的血流动力学不稳定是一种危及生命的状况,需要使用血管升压药和重要器官支持。已证明使用Cytosorb进行血液吸附可有效减少细胞因子,并可能减轻因对初始损伤的免疫过度反应引发的细胞因子风暴的破坏性影响。我们检索了PubMed数据库,以评估Cytosorb对重症患者去甲肾上腺素需求影响的证据。我们在一项比较汇总分析中进一步分析了那些包含对照队列数据的研究,将治疗效果定义为24小时血管升压药剂量相对减少的标准化平均差异。文献检索共获得33项符合条件的研究。我们发现治疗后去甲肾上腺素需求量显著降低的证据:治疗前中位数为0.55(IQR:0.39 - 0.90);治疗后为0.09(0.00 - 0.25)μg/kg/min,P < 0.001。24小时时汇总效应量较大,尽管具有高度异质性。鉴于迅速解决重症患者血流动力学不稳定的重要性,鼓励进一步开展研究以丰富对该治疗潜力的认识。